{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:16:40Z","timestamp":1782757000867,"version":"3.54.5"},"reference-count":134,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.drudis.2019.04.007","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T11:26:00Z","timestamp":1554895560000},"page":"1116-1131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art"],"prefix":"10.1016","volume":"24","author":[{"given":"Fatemeh","family":"Vahdat Lasemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mahjoubin Tehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hamid","family":"Aghaee-Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Jalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.04.007_bib0005","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1161\/STROKEAHA.115.008097","article-title":"Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease","volume":"46","author":"Mendis","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2019.04.007_bib0010","article-title":"Blood pressure targets for the treatment of people with hypertension and cardiovascular disease","volume":"10","author":"Saiz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drudis.2019.04.007_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijcard.2015.08.172","article-title":"Worldwide disparities in cardiovascular disease: challenges and solutions","volume":"202","author":"Okwuosa","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vhri.2017.05.003","article-title":"The economic costs of cardiovascular disease, diabetes mellitus, and associated complications in south asia: a systematic review","volume":"15","author":"Walker","year":"2018","journal-title":"Value Health Reg. Issues"},{"key":"10.1016\/j.drudis.2019.04.007_bib0025","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature06796","article-title":"Translating molecular discoveries into new therapies for atherosclerosis","volume":"451","author":"Rader","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.04.007_bib0030","first-page":"138","article-title":"[Dyslipidemia and atherosclerosis]","volume":"69","author":"Koba","year":"2011","journal-title":"Nippon Rinsho. Jpn. Clin. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/0003319718779533","article-title":"Pharmacological management of dyslipidemia in atherosclerosis: limitations, challenges, and new therapeutic opportunities","volume":"70","author":"Kypreos","year":"2018","journal-title":"Angiology"},{"key":"10.1016\/j.drudis.2019.04.007_bib0040","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","article-title":"New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?","volume":"27","author":"Sahebkar","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.drudis.2019.04.007_bib0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11094-012-0749-5","article-title":"The search for new drugs: some chemical and biochemical aspects of the problem of atherosclerosis","volume":"46","author":"Granik","year":"2012","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.drudis.2019.04.007_bib0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2016.07.897","article-title":"Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms","volume":"253","author":"Chru\u015bciel","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2019.04.007_bib0055","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40265-016-0591-2","article-title":"Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis","volume":"76","author":"Derosa","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2019.04.007_bib0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11745-010-3517-x","article-title":"Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial","volume":"46","author":"Parizadeh","year":"2011","journal-title":"Lipids"},{"key":"10.1016\/j.drudis.2019.04.007_bib0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2015.05.022","article-title":"Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials","volume":"241","author":"Sahebkar","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2019.04.007_bib0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2016.03.010","article-title":"Effects of statin therapy on augmentation index as a measure of arterial stiffness: a systematic review and meta-analysis","volume":"212","author":"Sahebkar","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0075","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.metabol.2015.08.002","article-title":"Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Sahebkar","year":"2015","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.drudis.2019.04.007_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.phrs.2015.10.013","article-title":"Statin therapy and plasma cortisol concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"103","author":"Sahebkar","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0085","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1160\/TH14-11-0937","article-title":"Association between statin use and plasma d-dimer levels: a systematic review and meta-analysis of randomised controlled trials","volume":"114","author":"Sahebkar","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2019.04.007_bib0090","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1160\/th15-08-0620","article-title":"The impact of statin therapy on plasma levels of von Willebrand factor antigen: systematic review and meta-analysis of randomised placebo-controlled trials","volume":"115","author":"Sahebkar","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2019.04.007_bib0095","doi-asserted-by":"crossref","first-page":"9902","DOI":"10.1038\/srep09902","article-title":"A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations","volume":"5","author":"Serban","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.04.007_bib0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.drudis.2019.04.007_bib0105","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14740338.2012.712959","article-title":"Statin drug interactions and related adverse reactions","volume":"11","author":"Bellosta","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.drudis.2019.04.007_bib0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","article-title":"Statin drug interactions and related adverse reactions: an update","volume":"17","author":"Bellosta","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.drudis.2019.04.007_bib0115","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.bbadis.2018.02.006","article-title":"Nutraceuticals as therapeutic agents for atherosclerosis","volume":"1864","author":"Moss","year":"2018","journal-title":"BBA Mol. Basis Dis."},{"key":"10.1016\/j.drudis.2019.04.007_bib0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2017.06.105","article-title":"Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy","volume":"248","author":"Zhao","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0125","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1038\/s41598-018-25835-5","article-title":"Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease","volume":"8","author":"Dai","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.04.007_bib0130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0135","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s40265-015-0466-y","article-title":"Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia","volume":"75","author":"Ito","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2019.04.007_bib0140","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0145","doi-asserted-by":"crossref","first-page":"21285","DOI":"10.1038\/srep21285","article-title":"In silico selection of an aptamer to estrogen receptor alpha using computational docking employing estrogen response elements as aptamer-alike molecules","volume":"6","author":"Ahirwar","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.04.007_bib0150","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/nat.2016.0611","article-title":"Ligand-guided selection of target-specific aptamers: a screening technology for identifying specific aptamers against cell-surface proteins","volume":"26","author":"Zumrut","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.drudis.2019.04.007_bib0155","doi-asserted-by":"crossref","first-page":"942","DOI":"10.15252\/msb.20156297","article-title":"Revisiting biomarker discovery by plasma proteomics","volume":"13","author":"Geyer","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0160","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur. Heart. J."},{"key":"10.1016\/j.drudis.2019.04.007_bib0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.med.55.091902.104408","article-title":"Progress in antisense technology","volume":"55","author":"Crooke","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0175","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","article-title":"Antisense oligonucleotides: from design to therapeutic application","volume":"33","author":"Chan","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0180","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/ph6070881","article-title":"New aspects of gene-silencing for the treatment of cardiovascular diseases","volume":"6","author":"Koenig","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2019.04.007_bib0185","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1345\/aph.1K065","article-title":"ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?","volume":"41","author":"Ito","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.drudis.2019.04.007_bib0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0076-6879(00)13003-4","article-title":"Progress in antisense technology: the end of the beginning","volume":"313","author":"Crooke","year":"2000","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0195","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12265-013-9495-7","article-title":"Antisense technology: an emerging platform for cardiovascular disease therapeutics","volume":"6","author":"Lee","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2015.01.007","article-title":"Preclinical and clinical development of siRNA-based therapeutics","volume":"87","author":"Ozcan","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.04.007_bib0205","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrg2968","article-title":"Current prospects for RNA interference-based therapies","volume":"12","author":"Davidson","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.drudis.2019.04.007_bib0210","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tibtech.2010.07.009","article-title":"RNAi and small interfering RNAs in human disease therapeutic applications","volume":"28","author":"Lares","year":"2010","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0215","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.1064023","article-title":"Argonaute2, a link between genetic and biochemical analyses of RNAi","volume":"293","author":"Hammond","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.04.007_bib0220","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","article-title":"Interfering with disease: a progress report on siRNA-based therapeutics","volume":"6","author":"de Fougerolles","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2019.04.007_bib0225","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2006","article-title":"Strategies for silencing human disease using RNA interference","volume":"8","author":"Kim","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.drudis.2019.04.007_bib0230","first-page":"467","article-title":"MicroRNA therapeutics: the next magic bullet? Mini Rev","volume":"15","author":"Simonson","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.drudis.2019.04.007_bib0235","first-page":"4051","volume":"23","author":"Lee","year":"2004","journal-title":"MicroRNA genes are transcribed by RNA polymerase II. EMBO J."},{"key":"10.1016\/j.drudis.2019.04.007_bib0240","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/nsmb1167","article-title":"RNA polymerase III transcribes human microRNAs","volume":"13","author":"Borchert","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0245","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature03049","article-title":"Processing of primary microRNAs by the Microprocessor complex","volume":"432","author":"Denli","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.04.007_bib0250","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1101\/gad.1262504","article-title":"The Drosha-DGCR8 complex in primary microRNA processing","volume":"18","author":"Han","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.drudis.2019.04.007_bib0255","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1261\/rna.5167604","article-title":"Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs","volume":"10","author":"Bohnsack","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.drudis.2019.04.007_bib0260","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.04.007_bib0265","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jjcc.2015.10.017","article-title":"Functions of microRNA-33a\/b and microRNA therapeutics","volume":"67","author":"Ono","year":"2016","journal-title":"J. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0270","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1196\/annals.1359.021","article-title":"Transcription factor decoys: a new model for disease intervention","volume":"1058","author":"Mann","year":"2005","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.drudis.2019.04.007_bib0275","series-title":"Targeted Drug Delivery: Concepts and Design. Advances in Delivery Science and Technology","article-title":"Targeted delivery of nucleic acid therapeutics via nonviral vectors","author":"Kapoor","year":"2015"},{"key":"10.1016\/j.drudis.2019.04.007_bib0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2019.04.007_bib0285","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.chembiol.2012.07.011","article-title":"Designing chemically modified oligonucleotides for targeted gene silencing","volume":"19","author":"Deleavey","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0290","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1039\/C4MD00184B","article-title":"Antisense oligonucleotides: modifications and clinical trials","volume":"5","author":"Sharma","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.drudis.2019.04.007_bib0295","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/CIRCRESAHA.117.310610","article-title":"A new approach to PCSK9 therapeutics","volume":"120","author":"Wang","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0300","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-Acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0305","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.2174\/13816128113199990312","article-title":"Apolipoprotein B antisense inhibition - update on mipomersen","volume":"19","author":"Gebhard","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.drudis.2019.04.007_bib0310","doi-asserted-by":"crossref","first-page":"19A","DOI":"10.1016\/j.amjcard.2016.05.028","article-title":"Novel therapies for low-density lipoprotein cholesterol reduction","volume":"118","author":"Toth","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0315","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 Phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0320","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0325","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein b synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacl.2014.12.008","article-title":"Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia","volume":"9","author":"Santos","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0335","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2014.12.006","article-title":"Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"9","author":"Panta","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0340","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0345","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0350","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.04.007_bib0355","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2019.04.007_bib0360","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0365","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","article-title":"Cross-species comparison of in vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100","volume":"77","author":"Yu","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0370","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1194\/jlr.M011791","article-title":"Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-defi cient mice","volume":"52","author":"Mullick","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0375","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2013.04.001","article-title":"The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin\/kexin 9 inhibitors","volume":"73","author":"Shen","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"Suppl","key":"10.1016\/j.drudis.2019.04.007_bib0380","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0385","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.drudis.2019.04.007_bib0390","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"20","author":"Lindholm","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2019.04.007_bib0395","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J. Lipid. Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0400","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.04.007_bib0405","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0410","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0415","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase I trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.04.007_bib0420","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","article-title":"Overproduction of large VLDL particles is driven by increased liver fat content in man","volume":"49","author":"Adiels","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2019.04.007_bib0425","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2337\/dc09-1765","article-title":"Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet","volume":"33","author":"Chan","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2019.04.007_bib0430","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.259","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study","volume":"88","author":"Sanwald-Ducray","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.04.007_bib0435","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1194\/jlr.M005108","article-title":"Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia","volume":"51","author":"Sundaram","year":"2010","journal-title":"J. Lipid. Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040113","article-title":"Lipoprotein genotype and conserved pathway for exceptional longevity in humans","volume":"4","author":"Atzmon","year":"2006","journal-title":"PLoS Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0445","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0450","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1194\/jlr.M900346-JLR200","article-title":"Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions","volume":"51","author":"Sundaram","year":"2010","journal-title":"J. Lipid. Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0455","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.2174\/138161210793292492","article-title":"HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders","volume":"16","author":"Getz","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2019.04.007_bib0460","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/11594190-000000000-00000","article-title":"Apolipoprotein E mimetics and cholesterol-lowering properties","volume":"11","author":"Sharifov","year":"2011","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"10.1016\/j.drudis.2019.04.007_bib0465","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.atherosclerosis.2012.05.040","article-title":"Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice","volume":"224","author":"Nayyar","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2019.04.007_bib0470","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejphar.2013.11.004","article-title":"Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma","volume":"723","author":"Yamamoto","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0475","series-title":"Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for CardioMetabolic Diseases at American Heart Association Scientific Sessions 2014","author":"Alnylam","year":"2014"},{"key":"10.1016\/j.drudis.2019.04.007_bib0480","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drudis.2019.04.007_bib0485","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0490","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1194\/jlr.M066399","article-title":"Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: Phase 2 randomized trial results","volume":"57","author":"Yang","year":"2016","journal-title":"J. Lipid. Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0495","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0500","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2019.04.007_bib0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2017.06.059","article-title":"The approach study: a randomized, double-blind, placebo\u2013controlled, Phase III study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS)","volume":"263","author":"Gaudet","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2019.04.007_bib0510","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.atherosclerosissup.2017.08.003","article-title":"Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): A randomized, double-blind, placebo-controlled trial","volume":"28","author":"Gouni-Berthold","year":"2017","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.drudis.2019.04.007_bib0515","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.drudis.2019.04.007_bib0520","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","article-title":"Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids","volume":"33","author":"Robciuc","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0525","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0530","article-title":"A Subcutaneous Platform for RNAi Therapeutics Targeting Metabolic Diseases: PCSK9 and ANGPTL3","author":"Borodovsky","year":"2013","journal-title":"Alnylam Pharmaceuticals"},{"key":"10.1016\/j.drudis.2019.04.007_bib0535","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2019.04.007_bib0540","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2019.04.007_bib0545","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1194\/jlr.M029215","article-title":"Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein","volume":"54","author":"Lee","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.drudis.2019.04.007_bib0550","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.celrep.2017.10.023","article-title":"Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis","volume":"21","author":"Price","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2019.04.007_bib0555","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/ATVBAHA.113.301732","article-title":"Therapeutic silencing of MicroRNA-33 inhibits the progression of atherosclerosis in Ldlr\u2013\/\u2013 mice - Brief report","volume":"33","author":"Rotllan","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0560","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/ATVBAHA.116.308916","article-title":"MicroRNA-33 regulates macrophage autophagy in atherosclerosis","volume":"37","author":"Ouimet","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0565","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121","author":"Rayner","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2019.04.007_bib0570","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/ATVBAHA.112.300639","article-title":"Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"33","author":"Marquart","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0575","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.15252\/emmm.201404046","article-title":"Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice","volume":"6","author":"Goedeke","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.drudis.2019.04.007_bib0580","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.04.007_bib0585","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0590","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0595","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.26","article-title":"Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice","volume":"5","author":"Yu","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.drudis.2019.04.007_bib0600","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-ApoARx and IONIS-ApoA-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0605","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled Phase I study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.04.007_bib0610","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mtc.2001.111204","article-title":"Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy","volume":"121","author":"Ehsan","year":"2001","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.drudis.2019.04.007_bib0615","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0140-6736(99)09405-2","article-title":"Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial","volume":"354","author":"Mann","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.04.007_bib0620","series-title":"American Heart Association Annual Meeting (Late Breaking Clinical Trials)","article-title":"Phase II trial of the E2F decoy in coronary bypass grafting","author":"Grube","year":"2001"},{"key":"10.1016\/j.drudis.2019.04.007_bib0625","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jvs.2005.12.058","article-title":"Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery","volume":"43","author":"Conte","year":"2006","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.drudis.2019.04.007_bib0630","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.294.19.2446","article-title":"Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2019.04.007_bib0635","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ahj.2012.05.019","article-title":"Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results","volume":"164","author":"Lopes","year":"2012","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drudis.2019.04.007_bib0640","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and Safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","author":"Akdim","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2019.04.007_bib0645","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/eurheartj\/ehr148","article-title":"Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia","volume":"32","author":"Akdim","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2019.04.007_bib0650","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2019.04.007_bib0655","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: A randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2019.04.007_bib0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2019.04.007_bib0665","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2017.02.019","article-title":"Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)","volume":"259","author":"Waldmann","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2019.04.007_bib0670","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.tips.2018.09.005","article-title":"MicroRNAs: novel molecular targets and response modulators of statin therapy","volume":"39","author":"Mohajeri","year":"2018","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618305348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618305348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:40:48Z","timestamp":1761223248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618305348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1359644618305348"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.04.007","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}